中富通(300560.SZ):實控人陳融潔擬將7.04%股份協議轉讓予濟南鐵富
格隆匯1月12日丨中富通(300560.SZ)公佈,公司近日收到控股股東、實際控制人陳融潔的通知,獲悉其與濟南鐵富於2022年1月11日簽訂了《股份轉讓協議》,其擬以協議轉讓的方式以12.55元/股的價格向濟南鐵富轉讓其持有的公司無限售流通股15,936,255股,佔公司總股本的7.04%,股份轉讓價款合計2億元。
本次權益變動後,轉讓方及其一致行動人福建融嘉科技有限公司合計持有公司股份97,028,361股,佔公司總股本的42.88%,仍為公司控股股東及實際控制人;濟南鐵富持有公司股份15,936,255股,佔公司總股本的7.04%,成為公司持股5%以上的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.